The efficacy of intravesical bacillus Calmette-Guerin in the treatment of interstitial cystitis: Long-term followup

Journal of Urology

Volumn 159, Issue 5, 1998, Pages 1483-1487

  Peters, Kenneth M ^a   Diokno, Ananias C ^a   Steinert, Bruce W ^a   Gonzalez, Jose A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

BCG vaccine; Cystitis; Immunotherapy

Indexed keywords

BCG VACCINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPAREUNIA; DYSURIA; HUMAN; IMMUNOTHERAPY; INTERSTITIAL CYSTITIS; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032451196     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199805000-00019     Document Type: Article

References (23)

1. Hunner, G. L.: A rare type of bladder ulcer in women; report of cases. Boston Med. Surg. J., 172: 660, 1915.
2. Zeidman, E. J., Helfrick, B., Pollard, C. and Thompson, I. M.: Bacillus calmette-guérin immunotherapy for refractory interstitial cystitis. Urology, 43: 121, 1994.
3. Peters, K., Diokno, A., Steinert, B., Yunico, M., Mitchell, B., Krohta, S., Gillette, B. and Gonzalez, J.: The efficacy of intravesical Tice strain bacillus calmette-guerin in the treatment of interstitial cystitis: a double-blind, prospective, placebo controlled trial. J. Urol., 157: 2090, 1997.
4. Gillenwater, J. Y. and Wein, A. J.: Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases workshop on interstitial cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J. Urol., 140: 203, 1988.
5. Striker, G. E.: KUH Notes. J. Urol., 142: 139, 1989.
6. Ware, J. E., Jr. and Sherbourne, C. D.: The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med. Care, 30: 473, 1992.
7. Keller, M. L., McCarthy, D. O. and Neider, R. S.: Measurement of symptoms of interstitial cystitis. Urol. Clin. N. Amer., 21: 67, 1994.
8. Parsons, C. L., Benson, G., Childs, S. J., Hanno, P., Sant, G. R. and Webster, G.: A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J. Urol., 150: 845, 1993.
9. Liebert, M., Wedemeyer, G., Stein, J. A., Washington, R., Jr., Faerber, G., Flint, A. and Grossman, H. B.: Evidence of urothelial cell activation in interstitial cystitis. J. Urol., 149: 470, 1993.
10. Christmas, T. J. and Bottazzo, G. F.: Abnormal urothelial HLA-DR expression in interstitial cystitis. Clin. Exp. Immunol., 87: 450, 1992.
11. Silk, M. R.: Bladder antibodies in interstitial cystitis. J. Urol., 103: 307, 1970.
12. Joustra, B., Karrenbeld, A. and Mensink, H.: Specific autoantibodies in interstitial cystitis patients suggest an autoimmune etiology. J. Urol., part 2, 155: 431A, abstract 483, 1996.
13. Keay, S., Zhang, C. O., Trifillis, A. L., Hebel, J. R., Jacobs, S. C. and Warren, J. W.: Urine autoantibodies in interstitial cystitis. J. Urol., 157: 1083, 1997.
14. Ochs, R. L., Muro, Y., Chan, E. K. L., Tan, E. M. and Keck, W. M.: Autoantibodies to DFS70 in patients with interstitial cystitis or atopic dermatitis (abstract). International Research Symposium on Interstitial Cystitis, Washington, D. C., p. 80, 1997.
15. Mosmann, T. R. and Moore, K. W.: The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol. Today, 12: A49, 1997.
16. 1-dominant type after varicella-zoster virus infection in atopic dermatitis. J. Allergy Clin. Immunol., 100: 274, 1997.
17. Lotz, M., Villiger, P., Hugli, T., Koziol, J. and Zuraw, B. L.: Interleukin-6 and interstitial cystitis. J. Urol., 152: 869, 1994.
18. Shingleton, W. B. and Fleischmann, J.: Urinary interleukin-2 inhibitor and the voiding symptoms in women patients with interstitial cystitis. Sem. Urol., 9: 120, 1991.
19. Rook, G. A. W. and Stanford, J. L.: Adjuvants, endocrines and conserved epitopes: factors to consider when designing "therapeutic vaccines". Int. J. Immunopharmacol., 17: 91, 1995.
20. Bohle, A., Nowc, C. H., Ulmer, A. J., Musehold, J., Gerdes, J., Hofstetter, A. G. and Flad, H. D.: Elevations of cytokines interleukin 1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus calmette-guerin immunotherapy. J. Urol., 144: 59, 1990.
21. Kaempfer, R., Gerez, L., Farbstein, H., Madar, L., Hirschman, O., Nussinovich, R. and Shapiro, A.: Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J. Clin. Oncol., 14: 1778, 1996.
22. Smith, S. D., Wheeler, M. A., Foster, H. E. and Weiss, R. M.: Improvement in interstitial cystitis symptom scores during treatment with oral 1-arginine. J. Urol., 158: 703, 1997.
23. Chambers, M. A., Marshall, B. G., Wangroo, A., Bune, A., Cook, H. T., Shaw, R. J. and Young, D. B.: Differential responses to challenge with live and dead mycobacterium bovis bacillus calmette-guerin. J. Immunol., 158: 1742, 1997.